Tiziana Life Sciences Ltd (TLSA)
| Market Cap | 118.09M -48.8% |
| Revenue (ttm) | n/a |
| Net Income | -25.19M |
| EPS | -0.20 |
| Shares Out | 128.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,570 |
| Open | 0.8900 |
| Previous Close | 0.8720 |
| Day's Range | 0.8800 - 0.9300 |
| 52-Week Range | 0.7615 - 2.1000 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 8.08 (+776.41%) |
| Earnings Date | May 1, 2026 |
About TLSA
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TLSA stock is "Strong Buy." The 12-month stock price target is $8.08, which is an increase of 776.41% from the latest price.
News
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its l...
Tiziana Life Sciences doses last patient in foralumab trial
Tiziana Life Sciences (TLSA) announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in patients with early/mild A...
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its l...
Tiziana Life submits request to U.S. FDA for ODD for intranasal foralumab
Tiziana Life Sciences (TLSA) announced that it has submitted a request to the U.S. Food and Drug Administration, FDA, for Orphan Drug Designation, ODD, for intranasal foralumab for the treatment…
Tiziana Life announces first 3 participants received first dose in ALS BANYAN
Tiziana Life Sciences (TLSA) announced that the first three participants have all received their first dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The…
Tiziana Life Sciences announces last patient completed Phase 2a INFORM-MS trial
Tiziana Life Sciences (TLSA) announced that the last patient has completed their last visit in the Company’s Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Seconda...
Tiziana Life Sciences signs MOU with KAIMRC in Saudi Arabia
Tiziana Life Sciences (TLSA) announced the signing of a memorandum of understanding, or MOU, with the King Abdullah International Medical Research Center, or KAIMRC, of King Saud bin Abdulaziz Univers...
Tiziana Life Sciences initiated with a Buy at BTIG
BTIG initiated coverage of Tiziana Life Sciences (TLSA) with a Buy rating and $7 price target The clinical-stage biotechnology company is focused on using the anti-CD3 antibody foralumab to stimulate…
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its l...
Tiziana Life Sciences CEO Ivor Elrifi purchases 321,423 shares
Tiziana Life Sciences (TLSA) announced that its CEO, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the company’s common shares on NASDAQ at $1.00 per share,…
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its l...
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 m...
Tiziana Life Sciences chairman Gabriele Cerrone purchases 42,357 shares at 99c
Tiziana Life Sciences (TLSA) announced that its executive chairman and founder, Gabriele Cerrone, through Panetta Partners, an entity in which he has a beneficial interest, has increased his holdings ...
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its l...
Tiziana Life Sciences doses last patient in intranasal foralumab trial
Tiziana Life Sciences (TLSA) announced that the last patient in its ongoing Phase 2a clinical trial has received their first dose of intranasal foralumab for the treatment of non-active Secondary…
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary Pro...
Tiziana Life Sciences chairman Gabriele Cerrone purchases 15,000 shares
Tiziana Life Sciences (TLSA) announced that its executive chairman and founder, Gabriele Cerrone, through Panetta Partners, an entity in which he has a beneficial interest, has increased his holdings ...
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 mo...
Tiziana fully enrolls Phase 2 placebo-controlled MS trial
Tiziana Life Sciences (TLSA) announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patient...
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 mo...
Tiziana Life Sciences announces updated intranasal foralumab data
Tiziana Life Sciences (TLSA) announced updated clinical data from its ongoing expanded access program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Scle...
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Tiziana Phase 2 trial for foralumab shows reduced brain inflammation
Tiziana Life Sciences (TLSA) announced initial quantitative PET imaging results from the first two patients with Multiple System Atrophy in a Phase 2 clinical trial treated with intranasal foralumab. ...
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 mo...
Tiziana Life announces publication of preclinical data in bioRxiv preprint
Tiziana Life Sciences (TLSA) announces the publication of positive preclinical data in a bioRxiv preprint. The study, titled “Intranasal Anti-CD3 Antibody Treatment Attenuates Post COVID Neuroinflamma...